Given the variety of PD-1 expression patterns in intratumoral CD8+ T cells and CD25+ Tregs, we evaluated the therapeutic efficacy of CD25-targeted NIR-DPR combined with PD-1 blockade using multiple syngeneic murine tumor models. The gene discussed is CD8A; the disease is neoplasm.